Results from VERTIS CV (Evaluation of Ertugliflozin Efficacy and Safety Cardovascular Outcomes) trial were a bit disappointing. Erugliflozin (a SGLT-2 inhibitor) did meet the its primary endpoint of noninferiority for major adverse heart (cardiovascular) events compared to placebo in persons with type 2 diabetes and established (diagnosed) heart disease (bottom line: ertugliflozin does NOT increase risk for major adverse heart events). However, it did not achieve secondary endpoints in superiority compared to placebo for composite of CV (heart related) death or hospitalization for heart failure, CV (heart related) death alone, and renal (kidney related) death (bottom line: ertugliflozin does NOT decrease risk of CV (heart related) or renal (kidney related) death in a person with diabetes and established cardiovascular (heart) conditions).
Because we know diabetes does not happen in a silo and is often associated with cardiovascular (heart) and renal (kidney) conditions, the ideal is to have a diabetes medication that provides also heart and kidney related benefits. Bottom line is that ertugliflozin does NOT provide these benefits.
Please share your thoughts and subscribe to receive my blogs.
#ertugliflozin #diabetes #cardiovascular
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram.